Vascular News and Research

RSS

FDA approves Arteriocyte's Magellan MAR01 technology for Phase I trial to treat CLI

Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.

29 Jan 2011

The Methodist Hospital in Houston opens surgical training center

Today The Methodist Hospital in Houston opened the Methodist Institute for Technology, Innovation and Education, a 35,000 square-foot interactive, simulation-based surgical training center created to help practicing physicians acquire new high-tech skills including image-guided therapies, surgical robotics and new techniques.

29 Jan 2011

Both absence of insulin and resistance to insulin are associated with defects in FAS

A key mechanism that appears to contribute to blood vessel damage in people with diabetes has been identified by researchers at Washington University School of Medicine in St. Louis.

28 Jan 2011

Single DNA variation linked to decreased risk of coronary disease in African-Americans

A team of scientists at Johns Hopkins and elsewhere has discovered that a single alteration in the genetic code of about a fourth of African-Americans helps protect them from coronary artery disease, the leading cause of death in Americans of all races.

28 Jan 2011

Study aims to determine risk of dementia, cognitive decline in middle-aged people

University of North Carolina at Chapel Hill researchers are co-leading a national study to examine whether middle-aged people's physical health influences their risk of dementia later in life.

28 Jan 2011

Boston Scientific reports first U.S. use of Blazer Open-Irrigated Catheter in BLOCk-CTI clinical trial

Boston Scientific Corporation today announced the first use of the Blazer® Open-Irrigated Catheter in the U.S. as part of the BLOCk-CTI clinical trial. BLOCk-CTI is a prospective, randomized trial evaluating the safety and effectiveness of the Blazer Open-Irrigated Catheter in patients with sustained or recurrent Type 1 atrial flutter.

28 Jan 2011

Baxter fourth quarter net income declines 26% to $423 million

Baxter International Inc. today announced its financial results for the fourth quarter of 2010, and provided its financial outlook for the first quarter and full-year 2011.

From Baxter International Inc. 27 Jan 2011

Major changes at Journal of Vascular and Interventional Radiology

The Journal of Vascular and Interventional Radiology-the monthly, peer-reviewed flagship publication of the Society of Interventional Radiology-announced several major changes for 2011-all directed at highlighting the global impact of this minimally invasive medical specialty and its lead journal.

27 Jan 2011

AVRF and UPEI collaboration awarded Innovation PEI Pilot and Discovery Fund grant

Atlanta Vascular Research Foundation (AVRF), together with its collaborators at the University of Prince Edward Island (UPEI), has been awarded an Innovation PEI Pilot and Discovery Fund grant by Innovation PEI. The grant is to continue research and development in combining nutraceuticals to magnify clinical benefits for the prevention and treatment of cardiovascular and metabolic diseases. The funding from this grant is $25,000.

27 Jan 2011

IDEV announces release of SUPERA stent data from Leipzig Registry

IDEV Technologies, Incorporated, an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced the release of two-year European data from the prominent Leipzig Registry, which tracks patients treated with the SUPERA wire interwoven nitinol stent.

27 Jan 2011

FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness

Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced it has been granted Food and Drug Administration conditional Investigational Device Exemption approval to evaluate the safety and effectiveness of its CorPath® 200 System in delivering and manipulating coronary guidewires and stent/balloon systems in percutaneous coronary interventions procedures.

27 Jan 2011

FDA Advisory Committee recommends expanded indication for Abbott's RX ACCULINK Carotid Stent System

Abbott today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted that, for symptomatic and asymptomatic carotid artery disease patients at standard surgical risk, there is reasonable assurance that the benefits of the RX ACCULINK® Carotid Stent System outweigh its risks (Yes: 7, No: 3, Abstain: 1).

27 Jan 2011

Tryton initiates enrollment in Side Branch Stent System study

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first U.S. patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease.

27 Jan 2011

Boston Scientific initiates enrollment in comparative Chinese study of PROMUS Element Everolimus-Eluting Stent

Boston Scientific Corporation today announced the beginning of patient enrollment in the PLATINUM China clinical trial, which is designed to evaluate the safety and effectiveness of the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent compared to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent in the treatment of patients with a single de novo atherosclerotic lesion.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

APIC announces initiative to eliminate central line-associated bloodstream infections

The Association for Professionals in Infection Control and Epidemiology today announced a major initiative to eliminate one of the most preventable and deadly infections that patients can acquire in healthcare facilities: central line-associated bloodstream infections, which kill 30,000 people in the U.S. every year.

25 Jan 2011

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Glioblastoma, the most common and lethal form of brain cancer and the disease that killed Massachusetts Senator Ted Kennedy, resists nearly all treatment efforts, even when attacked simultaneously on several fronts. One explanation can be found in the tumor cells' unexpected flexibility, discovered researchers at the Salk Institute for Biological Studies.

25 Jan 2011

Human model of rare genetic disease reveals new clues to aging process

Scientists from A*STAR's Institute of Medical Biology (IMB) in Singapore and the University of Hong Kong's Department of Medicine have produced the world's first human cell model of progeria, a disease resulting in severe premature ageing in one in four to eight million children worldwide. This model has allowed them to make new discoveries concerning the mechanism by which progeria works.

25 Jan 2011

Boston Scientific completes enrollment in comparison trial of SYNERGY Stent to PROMUS Element Stent

Boston Scientific Corporation today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY™ Coronary Stent. The randomized, single-blind, non-inferiority trial will compare the SYNERGY Stent to the PROMUS Element™ Everolimus-Eluting Coronary Stent in patients with a single de novo native coronary artery lesion.

24 Jan 2011

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

The Methodist DeBakey Heart & Vascular Center was chosen today as a site for a critical percutaneous heart valve study. As part of the research study, Methodist physicians will replace diseased cardiac valves through a single, tiny puncture hole in the research subject's groin.

24 Jan 2011

Vascular News and Research

FDA approves Arteriocyte's Magellan MAR01 technology for Phase I trial to treat CLI

The Methodist Hospital in Houston opens surgical training center

Both absence of insulin and resistance to insulin are associated with defects in FAS

Single DNA variation linked to decreased risk of coronary disease in African-Americans

Study aims to determine risk of dementia, cognitive decline in middle-aged people

Boston Scientific reports first U.S. use of Blazer Open-Irrigated Catheter in BLOCk-CTI clinical trial

Baxter fourth quarter net income declines 26% to $423 million

Major changes at Journal of Vascular and Interventional Radiology

AVRF and UPEI collaboration awarded Innovation PEI Pilot and Discovery Fund grant

IDEV announces release of SUPERA stent data from Leipzig Registry

FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness

FDA Advisory Committee recommends expanded indication for Abbott's RX ACCULINK Carotid Stent System

Tryton initiates enrollment in Side Branch Stent System study

Boston Scientific initiates enrollment in comparative Chinese study of PROMUS Element Everolimus-Eluting Stent

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

APIC announces initiative to eliminate central line-associated bloodstream infections

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Human model of rare genetic disease reveals new clues to aging process

Boston Scientific completes enrollment in comparison trial of SYNERGY Stent to PROMUS Element Stent

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News